To sum things up.4 Mar 2021 18:12
Part 1.
A look at the shareholders of e-therapeutics plc (LON: ETX) can tell us which group is most powerful. Institutions often hold stocks in larger companies, and we expect insiders to own a significant percentage of the smaller companies. Warren Buffett said he likes "a company that has an enduring competitive advantage and is run by capable, owner-centric people." So it's nice to see inside ownership as it could suggest the management is owner driven.
With a market cap of £ 103 million in the UK, E-Therapeutics is a small cap stock that may not be well known to many institutional investors. Our analysis of ownership of the company below shows that institutional investors have participated in the company. We can expand the different groups of owners to learn more about e-therapeutics.
Check out our latest analysis for e-therapeutics
Breakdown of property
What does institutional ownership tell us about e-therapeutics?
Institutions usually measure themselves against a benchmark when reporting to their own investors. As a result, they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutes on their register, especially as they grow.
e-therapeutics already has institutions in the share register. Indeed, they have a respectable stake in the company. This suggests some credibility with professional investors. But we cannot rely on this fact alone, as institutions sometimes make bad investments, as everyone does. If several institutions own a share, there is always the risk that they are in a "crowded trade". When such a trade goes wrong, multiple parties can compete to sell stocks quickly. This risk is higher in a company with no history of growth. You can see E-Therapeutics' historical earnings and earnings below, but keep in mind that there is always more to history.
Profit and sales growth
E-Therapeutics is not part of hedge funds. Richard Griffiths is currently the largest shareholder with 21% of the issued shares. Ahmad Mortazavi is the second largest shareholder with 12% of the common stock, and Robert Quested holds approximately 12% of the company's stock. Ahmad Mortazavi, the second largest shareholder, also happens to be the Chief Executive Officer.
On closer inspection, we found that 52% of the shares are owned by the top 4 shareholders. In other words, these shareholders have a significant say in the company's decisions.
Sign In
Follow the stocks
